Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Certara (CERT)
NASDAQ:CERT
Holding CERT?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.12Last Year’s EPS
$0.09Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: -1.83%
|Next Earnings Date:Feb 27, 2025
Earnings Call Sentiment|Neutral
The earnings call highlights Certara's strong revenue growth, successful acquisitions, and advancements in biosimulation and AI, which are driving demand and bookings. However, challenges in the regulatory services market and lengthened decision-making processes among larger customers have led to a cautious outlook and guidance revision.Company Guidance
In the third quarter of 2024, Certara reported revenue of $94.8 million, representing an 11% year-over-year increase. This growth was primarily driven by their biosimulation strategy, which saw bookings rise by 13% to $96.1 million. The software segment contributed $35.9 million, marking a 15% increase, with a net retention rate of 108%. Meanwhile, services revenue increased by 9% to $58.9 million. Adjusted EBITDA improved to $33.1 million with a margin of 35%. Certara revised its full-year 2024 guidance to reflect the Chemaxon acquisition, projecting total revenue between $380 million and $385 million, and adjusted EBITDA between $120 million and $124 million. The company noted stable and improved business activity among Tier 1 biopharma customers and a continued demand for biosimulation despite lengthened decision-making processes.Revenue and Growth
Certara reported a third quarter revenue of $94.8 million, marking an 11% increase from the previous year. Software revenue increased by 15% to $35.9 million, with software bookings rising by 28%.
Successful Acquisition and Integration
Certara completed the Chemaxon acquisition, expanding its biosimulation reach into the preclinical market. The acquisition is expected to contribute approximately $5 million in revenue for the fourth quarter.
Biosimulation Demand and High Win Rates
Certara experienced high demand for biosimulation services, maintaining a very high win rate and observing increased biosimulation services utilization.
AI and Software Advancements
The integration of AI into Certara's platforms has led to the successful launch of CoAuthor in the regulatory writing market, generating significant customer interest and revenue.
Strong Software Bookings
Software bookings for the third quarter were $34.8 million, increasing 28% from the prior year period, with strong performance across Tier 1 and Tier 3 customers.
---
CERT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CERT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $10.91 | $10.99 | +0.73% |
| Aug 06, 2024 | $15.08 | $13.03 | -13.59% |
| May 07, 2024 | $17.66 | $16.35 | -7.42% |
| Feb 29, 2024 | $16.88 | $18.30 | +8.41% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Certara (CERT) report earnings?
Certara (CERT) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is Certara (CERT) earnings time?
Certara (CERT) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CERT EPS forecast?
CERT EPS forecast for the fiscal quarter 2024 (Q4) is $0.12.
---